Selected angiogenic cytokines in systemic lupus erythematosus patients

Autoimmunity

Volumn 42, Issue 5, 2009, Pages 459-466

  Hrycek, Antoni ^a   Janowska, Joanna ^a   Cieślik, Paweł ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Angiogenic cytokines; Females; Serum; Systemic lupus erythematosus; Therapy

Indexed keywords

AZATHIOPRINE; BASIC FIBROBLAST GROWTH FACTOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GROWTH FACTOR; HEPATIC GROWTH FACTOR; PREDNISONE; QUINAGOLIDE; SOLUBLE VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1; SOLUBLE VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LONG TERM CARE; PROTEIN BLOOD LEVEL; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION;

ADULT; CYTOKINES; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 70349865059     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.1080/08916930902960339     Document Type: Article

References (33)

1. D'Cruz D. Vasculitis in systemic lupus erythematosus. Lupus 1998;7:270-274.
2. Cieślik P, Hrycek A, Kuciń ski P. Vasculopathy and vasculitis in systemic lupus erythematosus. Pol Arch Med Wewn 2008; 118:57-62.
3. Robak E, Woźnicka A, Sysa-Jedrzejowska A, Stepień H, Robak T. Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosus. Lupus 2002;11:348-355.
4. Heshmat NM, El-Kerdany TH. Serum levels of vascular endothelial growth factor in children and adolescents with systemic lupus erythematosus. Pediatr Allergy Immunol 2007; 18:346-353.
5. Robak E, Kulczycka L, Tomczak J, Sysa-Jedrzejowska A. The role of angiogenesic cyto-kines in systemic lupus erythematosus pathogenesis. Acta Haematol Pol 2006;37:47-59.
6. Navarro C, Candia-Zúň iga L, Silveria LH, Ruiz V, Gaxiola M, Avila MC, Amigo MC. Vascular endothelial growth factor plasma levels in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Lupus 2002;11: 21-24.
7. Sezar O, Jakob Ch, Eucker J, Niemöller K, Gatz F, Wernecke K-D, Possinger K. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. Eur J Haematol 2001;66:83-88.
8. Jośko J, Gwóźdź B, Jeldrzejowska-Szypuka H, Hendryk H. Vascular endothelial growth factor (VEGF) and its effect on angiogenesis. Med Sci Monit 2000;6:1047-1052.
9. Kikuchi K, Kubo M, Kadono T, Yazawa N, Ihn H, Tamaki K. Serum concentration of vascular endothelial growth factor in collagen diseases. Br J Dermatol 1998;139:1049-1051.
10. Robak E, Woźniacka A, Sysa-Jeldrzejowska A, Stelpień H, Robak T. Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity. Eur Cyt Netw 2001;12:445-452.
11. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-1277.
12. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
13. Kuryliszyn-Moskal A, Klimuk PA, Sierakowski S, Ciolkiewicz M. Vascular endothelial growth factor in systemic lupus erythematosus: Relationship to disease activity, systemic organ manifestation, and nailfold capillaroscopic abnormalities. Arch Immunol Ther Exp 2007;55:179-185.
14. Robak E, Sysa-Jeldrzejowska A, Robak T. Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus. Mediators Inflamm 2003;12:293-298.
15. Robak E, Kulczycka L, Sysa-Jeldrzejowsla A, Woerzbowska A, Robak T. Circulating proangiogenic molecules PIGF, SDF-1 nad sVCAM-1 in patients with systemic lupus erythematosus. Eur Cytokine Netw 2007;18:181-187.
16. Yamasaki M. ETS family of transcription factors and the vascular system. In: Vascular complications in human disease. London: Springer-Verlag; 2008.
17. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993;90:10705-10709.
18. Yamaguchi S, Iwata K, Shibuya M. Soluble Fit-1(soluble VEGFR-1), a potent natural antiangiogenic molecule in mammals, is phylogenetically conserved in avians. Biochem Biophys Res Comm 2002;291:554-559.
19. Zaman K, Driscoll R, Hahn D, Werffeli P, Goodman SL, Bauer J, Leyvraz S, Lejeune F, Stupp R, Rüegg C. Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapy. Int J Cancer 2006;118:755-764.
20. ZiegenhagenMW, Fitschen J, Martinet N, Schlaak M, Müller- Quernheim J. Serum level of soluble tumor necrosis factor receptor II (75 kDa) indicates inflammatory activity of sarcoidosis. J Intern Med 2000;248:33-41.
21. Aringer M, Smolen JS. The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther 2008;10: 202, Epub 2008 Jan 23.
22. Studnicka-Benke A, Steiner G, Petera P, Smolen JS. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheum 1996;35:1067-1074.
23. Sabry A, Sheashaa H, El-Husseini A, Mahmoud K, Eldahshan KF,George SK,Abdel-Khalek E,El-Shafey EM, Abo-ZenahH. Proinflammatory cytokines (TNF-alpha and IL-6) in Egyptian patients with SLE: Its correlation with disease activity. Cytokine 2006;35:148-153. (Pubitemid 44666430)
24. Waszczykowska E, Robak E, Woźniacka A, Narbutt J, Torzecka JD, Sysa-Jełdrzejowska A. Estimation of SLE activity based on the serum level of chosen cytokines and superoxide radical generation. Med Inflam 1999;8:93-100.
25. Hrycek A, Cieślik P, Tustanowski J, Nowak S, Jedynak P. Selected serum cytokines in systemic lupus erythematosus treated with quinagolide. Lupus 2001;10:424-430.
26. Kadono T, Kikuchi K, Kubo M, Fujimoto M, Tamaki K. Serum concentrations of basic fibroblast growth factor in collagen diseases. J Am Acad Dermatol 1996;35:392-397.
27. Ohtsuka K, Gray JD, Stimmler MM, Toro B, Horwitz DA. Decreased production of TGF-b by lymphocytes from patients with systemic lupus erythematosus. J Immunol 1998;160: 2539-2545.
28. Lu L-Y, Cheng H-H, Sung P-K, Shiue J, Chen A. Singlenucleotide polymorphisms of transforming growth factor-beta1 in Taiwanese patients with systemic lupus erythematosus. J Microbiol Immunol Infect 2004;37: 145-152.
29. Hrycek A, Kuśmierz D, Dybała T, S ́ wiałtkowska L. Expression of messenger RNA for transforming growth factor-beta1 and for transforming growth factor-beta receptors in peripheral blood of systemic lupus erythematosus patients treated with low doses of quinagolide. Autoimmunity 2007;40:23-30.
30. Ohtsuka K, Gray JD, Stimmler MM, Horwitz DA. The relationship between defects in lymphocyte production of transforming growth factor-beta1 in systemic lupus erythematosus and disease activity or severity. Lupus 1999;8:90-94.
31. Hrycek A, Siekiera U, Cieślik P, Szkróbka W. HLA-DRB1 and-DQB1 alleles and gene polymorphisms of selected cytokines in systemic lupus erythematosus. Rheumatol Int 2005;26:1-6.
32. Capuano A, Constanzi S, Peluso G, Zannoni G, Vellone VG, Gremese E, Zoli A, Scott C, Beltrami CA, Romano G, Ferraccioli G. Hepatocyte growth factor and transforming growth factor b1 ratio at baseline can predict early response to cyclophosphamide in systemic lupus erythematosus nephritis. Arthritis Rheum 2006;54:3633-3639.
33. Liu Y, Zheng N, Yin WH, Zhang B. Relationship of serum levels of HGF and MMP-9 with disease activity of patients with systemic lupus erythematosus. Zhejiang Da Xue Xue Bao Yi Xue Ban 2004;33:340-343.